HALOZYME THERAPEUTICS, INC. (HALO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 344.44M USD | Liabilities, Current |
| Cash and equivalents | 163.14M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 453.33M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 137.13M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $344.44M | $163.14M | (m) | $453.33M | $137.13M | (m) |
| 2026-03-31 | (m) | $363.21M | $309.75M | (m) | $457.99M | $155.47M | (m) |
| 2025-12-31 | (m) | $177.09M | $133.82M | (m) | $426.27M | $176.47M | (m) |
| 2025-09-30 | (m) | $837.23M | $419.67M | (m) | $343.54M | $185.80M | (m) |
| 2025-06-30 | (m) | $134.28M | $61.86M | (m) | $315.07M | $181.50M | (m) |
| 2025-03-31 | (m) | $150.38M | $176.33M | (m) | $304.02M | $164.87M | (m) |
| 2024-12-31 | (m) | $139.10M | $115.85M | (m) | $288.20M | $141.86M | (m) |
| 2024-09-30 | (m) | $108.81M | $154.32M | (m) | $273.06M | $131.41M | (m) |
| 2024-06-30 | (m) | $133.36M | $187.86M | (m) | $210.42M | $159.31M | (m) |
| 2024-03-31 | (m) | $131.64M | $164.63M | (m) | $185.31M | $168.54M | (m) |
| 2023-12-31 | (m) | $112.49M | $118.37M | (m) | (m) | $127.60M | (m) |
| 2023-09-30 | (m) | $115.19M | $274.23M | (m) | $213.99M | $128.92M | (m) |
| 2023-06-30 | (m) | $116.39M | $221.16M | (m) | $221.69M | $132.41M | (m) |
| 2023-03-31 | $470.49M | $91.92M | $96.38M | $179.22M | $194.88M | $107.52M | 5.12× |
| 2022-12-31 | $593.87M | $130.79M | $234.19M | $128.60M | $231.07M | $100.12M | 4.54× |
| 2022-09-30 | $498.89M | $109.38M | $147.16M | $118.42M | $233.30M | $103.28M | 4.56× |
| 2022-06-30 | $398.73M | $199.51M | $90.93M | $118.43M | $189.37M | $97.61M | 2.00× |
| 2022-03-31 | $899.90M | $111.69M | $117.83M | $668.30M | $113.76M | $47.76M | 8.06× |
| 2021-12-31 | $831.90M | $117.15M | $118.72M | $622.20M | $90.97M | $53.91M | 7.10× |
| 2021-09-30 | $928.02M | $113.15M | $491.68M | $324.24M | $112.10M | $55.98M | 8.20× |
| 2021-06-30 | $908.50M | $114.25M | $446.97M | $308.34M | $153.20M | $58.55M | 7.95× |
| 2021-03-31 | $852.70M | $107.42M | $499.45M | $264.86M | $88.39M | $58.34M | 7.94× |
| 2020-12-31 | $465.74M | $421.38M | $147.70M | $220.31M | $97.73M | $60.75M | 1.11× |
| 2020-09-30 | $409.26M | $26.98M | $65.74M | $280.96M | $62.55M | $57.70M | 15.17× |
| 2020-06-30 | $422.85M | $26.07M | $133.61M | $251.84M | $37.40M | $48.27M | 16.22× |
| 2020-03-31 | $397.93M | $42.00M | $104.82M | $263.36M | $29.75M | $41.45M | 9.47× |
| 2019-12-31 | $480.70M | $85.64M | $120.18M | $301.08M | $59.44M | $29.36M | 5.61× |
| 2019-09-30 | $278.74M | $108.04M | $59.20M | $178.80M | $40.74M | $36.05M | 2.58× |
| 2019-06-30 | $319.68M | $135.42M | $67.04M | $220.42M | $32.22M | $43.90M | 2.36× |
| 2019-03-31 | $356.88M | $138.66M | $60.59M | $268.12M | $28.16M | $31.24M | 2.57× |
| 2018-12-31 | $384.53M | $149.36M | $57.94M | $296.59M | $30.00M | $22.63M | 2.57× |
| 2018-09-30 | $387.02M | $139.12M | $55.02M | $309.35M | $22.66M | $18.29M | 2.78× |
| 2018-06-30 | $422.48M | $132.43M | $55.17M | $343.72M | $23.58M | $8.40M | 3.19× |
| 2018-03-31 | $460.27M | $119.22M | $98.01M | $335.68M | $26.57M | $4.39M | 3.86× |
| 2017-12-31 | $491.35M | $131.33M | $168.74M | $300.47M | $22.13M | $5.15M | 3.74× |
| 2017-09-30 | $331.62M | $102.05M | $164.40M | $152.53M | $14.70M | $9.33M | 3.25× |
| 2017-06-30 | $312.01M | $82.61M | $114.75M | $182.79M | $14.47M | $15.17M | 3.78× |
| 2017-03-31 | $191.44M | $61.71M | $45.19M | $133.80M | $12.45M | $14.29M | 3.10× |
| 2016-12-31 | $220.66M | $54.59M | $66.76M | $138.22M | $15.68M | $14.62M | 4.04× |
| 2016-09-30 | $238.73M | $52.66M | $61.21M | $159.84M | $17.68M | $12.85M | 4.53× |
| 2016-06-30 | $253.22M | $38.88M | $61.23M | $168.76M | $23.23M | $10.76M | 6.51× |
| 2016-03-31 | $264.18M | $64.22M | $69.09M | $169.54M | $25.54M | $10.35M | 4.11× |
| 2015-12-31 | $140.75M | $62.46M | $43.29M | $65.05M | $32.41M | $9.49M | 2.25× |
| 2015-09-30 | $132.11M | $44.85M | $71.51M | $52.20M | $8.39M | $11.10M | 2.95× |
| 2015-06-30 | $150.45M | $35.04M | $67.77M | $72.95M | $9.74M | $7.72M | 4.29× |
| 2015-03-31 | $136.22M | $26.21M | $44.29M | $84.21M | $7.72M | $7.48M | 5.20× |
| 2014-12-31 | $144.77M | $24.33M | $61.39M | $74.23M | $9.15M | $6.41M | 5.95× |
| 2014-09-30 | $142.74M | $34.59M | $46.38M | $88.09M | $8.28M | $6.92M | 4.13× |
| 2014-06-30 | $160.54M | $31.72M | $56.13M | $91.51M | $12.89M | $7.11M | 5.06× |
| 2014-03-31 | $175.44M | $36.36M | $76.57M | $87.92M | $10.96M | $6.76M | 4.83× |
| 2013-12-31 | $80.60M | $25.45M | $27.36M | $44.15M | $9.10M | $6.17M | 3.17× |
| 2013-09-30 | $89.83M | $39.62M | $17.49M | $47.82M | $24.52M | $3.85M | 2.27× |
| 2013-06-30 | $86.84M | $32.83M | $27.93M | $48.08M | $10.83M | $2.47M | 2.64× |
| 2013-03-31 | (m) | $19.75M | $39.02M | (m) | $10.38M | $2.74M | (m) |
| 2012-12-31 | (m) | $18.95M | $99.90M | (m) | $15.70M | $2.67M | (m) |
| 2012-09-30 | (m) | $21.04M | $87.61M | (m) | $4.46M | $2.19M | (m) |
| 2012-06-30 | (m) | $16.15M | $102.04M | (m) | $5.69M | $1.78M | (m) |
| 2012-03-31 | (m) | $16.68M | $116.61M | (m) | $5.55M | $1.50M | (m) |
| 2011-12-31 | (m) | $17.30M | $52.83M | (m) | $2.26M | $567.26K | (m) |
| 2011-09-30 | (m) | $13.79M | $66.33M | (m) | $6.24M | $103.44K | (m) |
| 2011-06-30 | (m) | $31.54M | $79.12M | (m) | $4.50M | $83.85K | (m) |
| 2011-03-31 | (m) | (m) | $73.83M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $15.34M | $83.26M | (m) | $2.33M | $193.42K | (m) |
| 2010-09-30 | (m) | (m) | $89.84M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $41.31M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $67.46M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $63.72M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |